U.S.-based Biogen has not received any formal expressions of interest from potential buyers and is not actively soliciting takeover offers, says Reuters sources.
Earlier this week, rumors were swirling about potential interest from both Merck and Allergan.
However, nothing has been presented to Biogen's board for consideration recently and one reason for this is that Biogen would expect a premium price on any proposal due to its perceived value of its neurology drugs portfolio, said the source.
Read the Reuters coverage